Insights & Analysis

Industry insights that are curated and delivered to inform your dealmaking strategies. We select the most relevant information, providing a consistent, convenient source for exclusive intelligence and analysis.

Page 38

Activism

Activist Investing Today: Lazard’s Jim Rossman

By Ronald Orol
|
Published: February 18th, 2022
Rossman, a top corporate defender and banker, explains why a new disclosure rule is a 'big win' for companies while changes to proxy contest rules will open the floodgates to activists nominating director candidates.
M&A

Restaurants Catch Up on Tech

By Nikitha Sattiraju
|
Published: February 18th, 2022
Demand for new technology drives M&A, turning the attention to PE-backed companies such as HungerRush as acquirers and opportunities.
Podcasts

Drinks With The Deal: Kirkland's Eric Wedel

By David Marcus
|
Published: February 17th, 2022
Kirkland debt finance partner Eric Wedel discusses the evolution of the practice and how the emergence of capital markets desks at PE sponsors has changed it.
Activism

Activist Investing Today: Wachtell's Katz Discusses 13D Change

By Ronald Orol
|
Published: February 11th, 2022
David Katz, a top corporate defender, explains why he is excited that the nation’s securities regulator just issued new tougher transparency rules for activists that he has been pushing for over a decade.
Activism

Kohl’s Retains Goldman, Rejects Bids

By Ronald Orol
|
Published: February 4th, 2022
The activist-targeted department store chain rejects expressions of interest while noting it has retained Goldman Sachs — first reported last month in The Deal — to engage with interested parties.
M&A

Drinks With The Deal: Katten's Kimberly Smith

By David Marcus
|
Published: February 3rd, 2022
Kimberly Smith, head of the law firm's corporate department, discusses the current state of middle-market dealmaking, her work with family offices and increased regulatory scrutiny of even smaller deals.
M&A

CI Capital Sells Epiphany Dermatology

By Armie Margaret Lee
|
Published: February 3rd, 2022
The Deal reported in October that the PE firm was exploring a sale of the Austin, Texas-based dermatology company.